The estrogen receptor-related receptor gamma (ERRg/ERR3/NR3B3) is a member of the nuclear receptor superfamily that activates transcription in the absence of ligand. However, the detailed mechanism of gene regulation by ERRg is not fully understood. In this study we have found that the orphan nuclear receptor ERRg activates the DAX-1 promoter, which, in turn, represses transactivation by ERRg. Serial deletions of mouse DAX-1 (mDAX-1) gene promoter have revealed that the region responding to ERRg is located between À129 and À121 bp and À334 and À326 bp. Gel shift assays and chromatin immunoprecipitation (ChIP) assays demonstrated that ERRg binds directly to the mDAX-1 promoter. Site-directed mutagenesis results demonstrated that ERRE1 (À129 to À121 bp) is more important than ERRE2 (À334 to À326 bp) which is not conserved in the human DAX-1 promoter. In addition, adenovirus-mediated overexpression of ERRg induced DAX-1 gene expression in MCF-7 breast cancer cells that co-expressed ERRg and DAX-1. Moreover, yeast two-hybrid and glutathione S-transferase (GST)-pull down assays demonstrated that DAX-1 physically interacted with ERRg and inhibited ERRg transactivation, and that this interaction was dependent on the AF-2 domain of ERRg. In addition, in vitro competition assays showed that DAX-1 inhibited PGC-1a mediated ERRg transactivation, via competition between these two factors for the AF-2 binding domain. We thus propose a novel autoregulatory loop that controls DAX-1 gene expression by ERRg.
INTRODUCTION
Nuclear receptors (NRs) are ligand-dependent transcription factors that bind to specific DNA target sequences through their highly conserved DNA-binding domain (DBD) and activate transcription through interaction with coactivators. The latter property is dependent on their moderately conserved ligand-binding domain (LBD) and in particular requires the extreme C-terminal part of it, the so-called AF-2 region (1).
Among NRs, DAX-1 (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1) (NR0B1) is an atypical orphan nuclear receptor, since it does not contain a DBD (2, 3) . Instead, the N-terminal half of DAX-1 contains a unique region mainly composed of three repeats, each of which is 65-67 amino acids in length. This region contains LXXLL motif-like sequences (where L and M are leucine and methionine, respectively, and X can be any amino acid) that are necessary for interaction with estrogen receptors (ERs) (4) . Since the C-terminal half of DAX-1 containing the putative LBD functions as a repressor domain through interaction with corepressors (NCoR) (5), two mechanisms have been proposed to function cooperatively in the repression of transcription exerted by DAX-1. According to the proposition, DAX-1 would both block the binding of coactivators to NRs and recruit corepressors with its Cterminal half (4) (5) (6) . The DAX-1 gene was identified through a search for a gene linked to adrenal hypoplasia congenita, The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org a disease affecting the normal development of the adrenal cortex and which is often associated with hypogonadotropic hypogonadism (2, 3) . Mouse and human DAX-1 promoters have been cloned and characterized. For example, orphan nuclear receptor steroidogenic factor-1 (SF-1) regulates DAX-1 promoter, and the SF-1 response element is located between À129 and À121 bp on the mouse promoter and between À135 and À143 bp on the human promoter (7, 8) .
Estrogen-related receptors (ERRs-alpha, -beta and -gamma), are orphan NRs closely related to ERs, with which they share identical target response elements and coregulatory proteins (9, 10) . However, ERRs do not respond to the classical ER ligand. Previous studies have demonstrated that MCAD, pS2 and cyp19 are targets of ERRa (11) (12) (13) . Among the ERR family, ERRg, the newest member of the subfamily, is a constitutively active nuclear receptor, and little is known about its in vivo functions (9, 10) . Previous studies have demonstrated that 4-hydroxytamoxifen (4-OHT) directly binds to and deactivates ERRg, suggesting that 4-OHT is an inverse agonist of ERRg (14, 15) . However, the deactivation mechanism of ERRg by 4-OHT requires further elucidation. It has been reported that coactivators such as GRIP1 or PGC-1a, interact directly with ERRg and activate its transcriptional activity (16, 17) . ERRg acts as a monomer and activates transcription constitutively. It has also been suggested in recent reports, that ERRg forms dimers through its LBD. In contrast to this, the related receptor, ERRa, inhibits the activities of both ERRa and ERRg through heterodimerization (18) . ERRg exhibits significant affinities for binding to a wide spectrum of sequences, including inverted and direct repeat sequences composed of AGGTCA half-sites with differing spacings, as well as a monovalent motif of the same sequence carrying an extra T(C/G)A trinucleotide on the 5 0 side (19) . It has been reported that ERRg binds to and transactivates both estrogen response elements and SF-1 response elements (SF-1RE). Previous reports have suggested that several monomeric binding partners, such as SF-1, liver receptor homolog-1 (LRH-1) and ERRg, can activate and bind directly to the small heterodimer partner (SHP) promoter through SF-1RE (16, 20) . DAX-1 is closely related to SHP, which neither contains a DNA-binding domain nor functions as a corepressor (2, 3) . In addition, both the DAX-1 and SHP promoters are regulated by the monomer binding partner SF-1. Thus, since the DAX-1 promoter contains several SF-1RE, we predicted that ERRg could also activate the DAX-1 promoter. Transient transfection studies demonstrated that ERRg had a preferential effect on the DAX-1 promoter. The results of deletion and site-directed mutagenesis have revealed that two ERR regulatory elements (ERREs) are responsible for the ERRg-mediated activation of the DAX-1 promoter. The results of electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assays strongly suggest that ERRg binds directly to the DAX-1 promoter. In addition, the results of overexpression and ERRg knock-down experiments demonstrated that ERRg regulates DAX-1 gene expression in MCF-7 breast cancer cells and that ERRg and DAX-1 are co-expressed in breast cancer tissue. The expression of DAX-1 inhibits ERRg transactivation of its own promoter and DAX-1 competes directly with the coactivator, PGC-1a, for binding to ERRg. Taken together, these results suggest that ERRg belongs to a new autoregulatory loop that governs DAX-1 gene expression.
MATERIALS AND METHODS
Plasmids and DNA construction pcDNA3/HA-ERRa, b, and g (DAF-2), pcDNA3/HA SF-1, pcDNA3/HA DAX-1, pcDNA3/HA PGC-1a, pGEX4T-1 DAX-1, B42 ERRg, B42 DAF-2 ERRg, Lex A DAX-1, and pcDNA3 PGC-1a were described previously (21) (22) (23) . To generate the À467 bp DAX-1 promoter region, genomic DNA was isolated from a mouse testicular Leydig cell line, K28 and used as template for PCR. The PCR product was cloned into the pGL3-basic plasmid (Promega) between the MluI and XhoI sites. mDAX-1/Luc (À325 and À121 bp) were made by PCR using the primer and cloned into pGL3 at MluI and XhoI. Mutant reporters, mtERRE1/Luc, mtERRE2/Luc and mtERRE1&2/Luc, were constructed by site-directed mutagenesis of the mDAX-1 promoter À467 bp/Luc using the primer. The mutated sequences are shown in Figure 4A . All clones were verified by sequencing analysis.
Cell culture and transient transfection assay
Human embryonic kidney (293T), mouse fibriblast (NIH3T3) and human breast cancer (MCF-7) cells were maintained with DMEM in the presence of 10% fetal bovine serum and antibiotics (Gibco) in humidified air containing 5% CO 2 at 37 C. Cells were transfected, using Superfect and Effectene reagents (Qiagen Inc., Germany), according to the manufacturer's instructions. The total DNA used in each transfection was adjusted to 1 mg by adding the appropriate amount of pcDNA3 vector. Approximately 40-48 h post-transfection, cells were harvested and luciferase activity was measured and normalized to b-galactosidase activity. Experiments were performed three times in duplicate.
Glutathione S-transferase (GST)-pull down assay
The indicated GST-fusion proteins or GST protein alone were expressed in Escherichia coli BL21 (DE3) pLys cultures by adding 0.2 mM isopropyl-b-D-thiogalactopyranoside (IPTG), and the cells were extracted. GST-fusion proteins were prebound with a 30 ml aliquot of glutathione-Sepharose beads. The beads were incubated with transcribed and translated [ 35 S]methionine-labeled proteins for 3-4 h at 4 C. The beads were then washed three times with the washing buffer, and analyzed by SDS-PAGE and protein bands were visualized by using a phosphorimaging analyzer. Translated proteins in vitro (10%) were used as input.
In vitro translation
ERRg and ERRg DAF-2 were transcribed and translated in vitro using a coupled rabbit reticulocyte system (Promega Corp., Madison, WI) in the presence of [ 35 S]methionine according to the manufacturer's instructions. The translated proteins were analyzed by 10% SDS-PAGE and visualized by autoradiography.
Yeast two-hybrid interaction assay
Yeast two-hybrid interaction assays were performed as described previously (22) . Briefly, LexA only or LexA fused plasmids, and B42 only or B42 fused plasmids, were transformed into Saccharomyces cerevisae EGY48, containing the galactosidase reporter plasmid 8H18-34, and transformants were selected on plates with the appropriate selection markers. The galactosidase assay on plates was carried out as described previously (22) .
Gel mobility shift assays
Double-stranded ERRE oligonucleotides were labeled by filling-in with [a-32 P]dCTP, using the Klenow fragment of DNA polymerase I. The oligonucleotide sequences are depicted in Figure 3A . Bacterially expressed GST only and GST fused ERRg were purified using GST-Sepharose beads (Amersham Bioscience, Inc.). Gel mobility shift assays (20 ml) contained 10 mM Tris (pH 8.0), 40 mM KCl, 0.05% Nonidet P-40, 6% glycerol, 1 mM DTT, and 1 mg of poly (dI-dC). Either 2 mg of GST only, or GST fused ERRg purified proteins, were used in each reaction. Competitor oligonucleotides were included at a 50-to 100-fold molar excess as indicated in the Figure legends. After 15 min incubation on ice, 10 000 c.p.m. of labeled oligonucleotide probe was added and incubation was continued for another 15 min. DNA-protein complexes were analyzed by 5% PAGE in 1· TBE. Gels were dried and analyzed by autoradiography.
ChIP assay
The ChIP assay was performed according to the instructions of the ChIP Assay Kit (Upstate, USA). 293T cells were transfected with 1 mg of pcDNA3 HA-ERRg or pcDNA3 HA and pGL3 À467 bp mDAX-1 using Effectene reagent (Qiagen Inc., Germany). The cells were fixed with formaldehyde 48 h after transfection and harvested. For immunoprecipitation, anti-HA antibody (Roche Molecular Biochemicals) was used. Final DNA extractions were amplified using pairs of primers that cover the ERR response region within the mDAX-1 promoter (nt À350 to À100 bp). The primers used for PCR were as follows: 
Preparation of recombinant adenovirus
The recombinant adenovirus was prepared as described previously (24) . In brief, the cDNA encoding ERRg was cloned into a pAd-YC2 shuttle vector, which (under the control of the cytomegalovirus promoter) contains a bovine growth hormone polyadenylation signal sequence. For homologous recombination, a pAd-YC2 shuttle vector (5 mg) and a rescue vector, pJM17 (5 mg), were co-transfected into human embryonic kidney 293 cells. To purify pure plaques, cell culture supernatant was serially diluted into serum-free media and incubated with 293 cells at 37 C for 1 h. An equal volume mixture of 2· medium and 1% agarose was overlaid on the 293 cells. After 7 days, plaques that were well isolated were purified further and propagated in 293 cells and screened by PCR, using upstream primers derived from the cytomegalovirus promoter, and downstream primers from the bovine growth hormone polyadenylation sequence. Then, the recombinants were amplified in 293 cells and were purified and isolated using CsCl 2 (Sigma). The preparations were collected and desalted, and titers were determined by counting the number of plaques.
Immunohistochemistry
Immunohistochemical analysis was performed with nine human breast cancer tissues. Three sections were cut from the paraffin blocks, deparaffinized antigen retrieval by pressure cooker in 10 mM sodium citrate (pH 6.0) at full power for 4 min. The primary antibodies used were rabbit polyclonal anti-ERRg (Abcam, 1:50) and anti-DAX-1 (Santa Cruz, 1:150). Immunohistochemistry was performed using an EnVision kit (DAKO, Carpinteria, CA). After preincubation with blocking serum for 15 min, the primary polyclonal antbody for ERRg or DAX-1 was added and incubated for 30 min in a humid chamber followed by a wash with TBS buffer. Slides were then incubated for 30 min with EnVision peroxidase reagent (DAKO, Carpinteria, CA).
The slides were then sequentially incubated with DAB (3,3-diaminobenzidine) chromogen for 5 min, counterstained with Meyer's hematoxylin and mounted. Careful rinses with several changes of TBS were performed between each stage of the procedure. To assess the specificity of the immunoreaction, a negative control without the primary antibody or with pre-immune rabbit serum was performed.
RT-PCR analysis
MCF-7 cells were infected with an adenovirus containing the ERRg gene (100 pfu/cells). After viral infection for 24 h, cells were harvested for total RNA isolation using the TRIzol reagent (Invitrogen Life Technologies) according to the manufacturer's protocol. The mRNAs of ERRg and DAX-1 were analyzed by RT-PCR. First-strand cDNA was synthesized from 1 mg of total RNA utilizing an anchored oligo(dT) primers and reverse transcriptase. The resulting first-strand cDNA was then amplified to measure mRNA levels of ERRg, DAX-1 and b-actin by realizing 28, 28 and 23 cycles of PCR using specific primers, respectively. The mRNA levels of b-actin served as an internal control for the RT-PCR analysis. The primers used for PCR of ERRg, DAX-1 and b-actin were as follows: ERRg, forward 5 0 -GACTTGACTCGCCA-CCTCTC-3 0 and reverse
0 -GTCATCACCATTGGCAATGAG and reverse 5 0 -CGTCATACTCCTGCTTGCTG-3 0 .
siRNA experiment
The siRNAs for ERRg (si-ERRg/I and /II) were chemically synthesized (Shamchully Pharm. Co., Ltd), deprotected, annealed, and transfected according to the manufacturer's instructions. MCF-7 cells were transfected with siRNA using Oligofectamine reagent (Invitrogen Life Technologies). After transfection for 48 h, total RNA was isolated for RT-PCR of ERRg (28 cycles 
RESULTS
Identification of ERRg as a transcriptional activator of the DAX-1 promoter SF-1 has been identified as an activator of the DAX-1 promoter (7, 8) . Since SFRE is also a DNA-binding site for ERRg, we speculated that an ERR response element (ERRE) exists in the DAX-1 promoter. As shown in Figure 1A , two ERREs were located in the mDAX-1 promoter; ERRE1 (À129 to À121 bp), which was previously identified as an SF-1RE, and a new ERRE2 (À334 to À326 bp). Interestingly, ERRE1 is conserved in both mouse and human promoters, whereas ERRE2 only exists in the mouse promoter ( Figure 1B) . In order to determine whether ERRs regulate the DAX-1 promoter, we performed transient transfection assays using the luciferase reporter gene driven by a À467 bp region from mouse DAX-1 promoter. As shown in Figure 2A and B, there was strong activation by ERRg in 293T cells and NIH3T3 cells, whereas ERRa and ERRb did not demonstrate any significant effect. As expected, SF-1, the positive control for the transfection assays, activated the DAX-1 gene promoter significantly. These results indicated that the DAX-1 gene is a specific target of ERRg, but not of ERRa or ERRb. In order to investigate the sequences that were required for ERRg mediated activation, a series of 5 0 deletions of the DAX-1 promoter were constructed, as shown in Figure 2C . Since the DAX-1 promoter contains two ERREs, we designed deletion constructs both with and without an ERRE. Activation by ERRg was decreased when the DAX-1 promoter was deleted up to À325 bp, as demonstrated in Figure 2D . Furthermore, the activation of the DAX-1 promoter by ERRg, was almost lost with the À121 bp DAX-1 construct. These results suggest that ERREs are required for ERRg response. À129 to À21 bp and À135 to À127 bp in mouse and human ERRE1, respectively, and À334 to À326 bp and À347 to À339 bp in mouse and human ERRE2, respectively.
Determination of ERRg binding regions
In order to clarify the specific binding of ERRg to ERREs, gel mobility shift assays were performed. As demonstrated in Figure 3A , we designed both wild-type and mutant probes that corresponded to ERRE1 and ERRE2. Previously, the TNAAGGTCA sequence was shown to be a bona fide ERRE. Within the sequence, the GG dimer is pivotal for ERRg protein binding. Thus, we substituted GG for the TT sequence. Figure 3B demonstrates that ERRg formed specific complexes with ERRE1 and ERRE2; a 50-or 100-fold molar excess of unlabeled ERRE1 and ERRE2 competed strongly with the DNA-protein complex. In order to verify that ERRg binds to the DAX-1 promoter in vivo, we performed a ChIP assay using PCR primers that flanked both ERRE1 and ERRE2 (À350 to À100 bp). 293T cells were transfected with the DAX-1 promoter, either with hemagglutinin (HA) only or with HA-tagged ERRg. As demonstrated in Figure 3C , a 250 bp PCR product (À350 to À100 bp) was observed in cells that were transfected with the expression vector for HA-ERRg but not with the vector expressing only the HA epitope. This indicated that HA-ERRg formed a specific complex with the DAX-1 promoter in vivo. Taken together, this suggests that ERRg regulates the DAX-1 promoter by direct binding to ERRE.
ERRE1 (À129 to À121 bp) is essential for transactivation of the DAX-1 promoter by ERRg
In order to verify the functional significance of ERRg binding sites in the DAX-1 promoter, site-directed mutagenesis was performed on the À467 bp DAX-1 promoter using the primers as shown in Figure 4A . Wild-type À467 bp/Luc and several mutant constructs were transiently transfected with ERRg into 293T cells. The ERRE1 mutation (mtERRE1/Luc) and double ERRE1 and ERRE2 mutations (mtERRE1&2/Luc) 3 and 4) . The À350 $ À100 bp fragment (250 bp) contains the ERRg binding site and 10% of the soluble chromatin used in the reaction was used as input (lanes 1 and 2) . PCR was performed as described in Figure 3C . completely abolished the ERRg-mediated transactivation of the DAX-1 promoter whereas the ERRE2 mutation (mtERRE2/Luc) had a slight effect ( Figure 4B ). These results indicated that ERRE1, rather than ERRE2, was essential for the activation of the DAX-1 promoter by ERRg. Thus, we conclude that ERRE1 plays a major role in the activation of the DAX-1 promoter by ERRg.
Induction of DAX-1 gene expression by ERRg in breast cancer
Previous reports have demonstrated that ERRg is a favorable biomarker and, possibly, an indicator of hormonal sensitivity in breast cancer. In addition, DAX-1 has also been detected in breast cancer tissue (25, 26) . In order to investigate whether ERRg can directly regulate DAX-1 gene expression in breast cancer cells, we introduced ERRg by adenovirus infection into MCF-7 cells. As demonstrated in Figure 5A , a basal expression of DAX-1 and ERRg was detected in MCF-7 cells, and DAX-1 mRNA was induced by overexpression of Ad-ERRg 24 h after infection. Since ERRg is basally expressed in MCF-7 cells, we further tested whether DAX-1 gene expression is down-regulated by performing knockdown of endogenous ERRg expression using small interfering RNA (si-ERRg/I or II) in MCF-7 cells. si-ERRg/I, but not si-ERRg/II significantly reduced endogenous ERRg expression ( Figure 5B ). DAX-1 mRNA level was decreased by knock-down of ERRg by si-ERRg/I, but not by si-ERRg/II, suggesting that endogenous ERRg can activate DAX-1 expression. In addition, CHIP assays were performed to confirm the direct binding of ERRg to the endogenous DAX-1 promoter in MCF-7 cells. As shown in Figure 5C , ERRg can bind to the DAX-1 promoter in MCF-7 cells ( Figure 5C ). Next, we analyzed for co-expression of DAX-1 and ERRg in human breast cancer tissues, using immunohistochemistry ( Figure 5D ). Nuclear immunoreactivity of DAX-1 was detected in breast cancer tissues. The overexpression of ERRg was observed in three out of nine cases. All of the ERRg-positive cancers co-expressed the DAX-1 protein ( Figure 5D, upper part) . Two cancer tissues that were DAX-1-negative were also negative for ERRg. No staining was observed in the negative controls using either pre-immune rabbit serum or by omitting the primary antibody (data not shown). These results suggest that ERRg can stimulate DAX-1 gene expression in human breast cancer cells.
DAX-1 represses ERRg transactivation of its own promoter
DAX-1 interacts with several orphan NRs (ER, AR, LRH-1, SF-1 and Nur77) and represses their transcriptional activity 1 and 2) . PCR was performed as described in Figure 5C (4-6,21,27). We investigated whether DAX-1 can also repress ERRg mediated transactivation of its own promoter. The results of transient transfections demonstrated that DAX-1 inhibits ERRg activity of the DAX-1 promoter in a dose-dependant manner ( Figure 6A ). Since ERRg also activates the SHP promoter, and SHP represses ERRg transactivation of its own promoter, we examined whether DAX-1 represses the ERRg-mediated transactivation of the SHP promoter or vice versa. As demonstrated in Figure 6B and C, DAX-1 and SHP repressed ERRg transactivation of both the SHP promoter and the DAX-1 promoter. These results suggest that both DAX-1 and SHP are regulated by ERRg and repress the transcriptional activity of ERRg through an autoregulatory loop. Since Figure 6A shows that DAX-1 repressed the transcriptional activity of ERRg, we examined whether DAX-1 can directly interact with ERRg, by using a GST-pull down and yeast twohybrid interaction assays. As demonstrated in Figure 7A and B, DAX-1 interacted with ERRg. Since repression or activation is dependant on the AF-2 domain, we deleted this domain in ERRg. As expected, DAX-1 could not interact with ERRg DAF-2, which demonstrates that the AF-2 domain of ERRg is crucial for the repressive effect of DAX-1 ( Figure 7A ). In the case of DAX-1, an LBD-like region was involved in the interaction with ERRg ( Figure 7B ). These results suggest that DAX-1 interacts directly with the AF-2 surface of ERRg.
Since the AF-2 surface of ERRg is involved in the interaction with DAX-1, we explored the role of coactivator competition in the repression of ERRg activity. As demonstrated in Figure 8A , PGC-1a, which was described previously as a coactivator of ERRg, significantly increased the activity of ERRg on the DAX-1 promoter and the co-expression of DAX-1 with PGC-1a repressed this induction in a dosedependant manner. This result suggests that both PGC-1a and DAX-1 compete for the binding of the AF-2 pocket of ERRg, as demonstrated for other receptors. In order to confirm the direct competition between DAX-1 and PGC-1a for binding to ERRg, we performed in vitro competition binding assays, using PGC-1a and DAX-1 with GST fused ERRg. The results of this study confirmed the findings of a previous report (17) . Specifically, 35 S-labeled PGC-1a interacted with ERRg, and DAX-1 inhibited the interaction between PGC-1a and ERRg ( Figure 8B ). In addition, no interaction between DAX-1 and PGC-1a occurred. Taken together, these observations suggest that DAX-1 physically inhibits the transcriptional activity of ERRg by competing with PGC-1a for interaction with ERRg.
DISCUSSION
ERRg is one of the newest members of the orphan nuclear receptor family. Therefore, the target and molecular mechanisms of ERRg have not yet been clearly identified. In this study, we demonstrated that ERRg acts as a potential regulator of DAX-1, which, in turn represses ERRg at a molecular level. This suggests the existence of an autoregulatory loop.
Although the physiological role of DAX-1 has been clearly identified, regulation of the DAX-1 promoter is not fully understood. A previous report demonstrated that SF-1 regulates the DAX-1 promoter through SFRE (7, 8) . Even though several SFREs are located on the DAX-1 promoter, the functional property of SFRE on the DAX-1 promoter has been characterized only in the region between À129 and À121 bp, which is conserved in both mouse and human (7) . As demonstrated in Figure 1 , ERRE1 is identical to sequences previously identified as the SFRE. We also characterized a new ERRE2 that was not previously identified as an SF-1RE. Although both ERRE1 and ERRE2 are required for the binding of ERRg, the data from mutation analysis suggest that ERRE1 is more responsible for ERRg transactivation than ERRE2 (Figures 3  and 4) . In the human DAX-1 promoter, only ERRE1 is present. However, SF-1 can still activate the DAX-1 promoter. This demonstrates that ERRE1 is critical for transactivarion (7) . Although all three members (a, b and g) of the ERR family bound to the same DNA response element (data not shown), only ERRg was able to activate the DAX-1 promoter (Figure 2 ). This suggests that DNA-binding is not completely responsible for transactivation.
The basal transcriptional activity of ERRa and b is relatively low compared to the high activity of ERRg. This suggests that the basal transcriptional mechanism governing ERRa and b may be distinct from that of ERRg. A previous report demonstrated that ERRg is constitutively active, because ERRg forms a complex with coactivators, such as SRC-1 (28) . It has been suggested that, depending on the specific co-regulator recruitment, transcriptional activity can be very different. Furthermore, since NRs can differentially modulate target promoters through the recruitment of different coregulators (29, 30) , ERRg may regulate target promoters, such as DAX-1, in a distinctly unique manner, compared to ERRa and b. Further investigation is necessary to determine whether ERRg regulation of target promoters differs with co-regulator recruitment.
Until recently, the ligand for ERRg was unknown, although 4-OHT was reported to be an inverse agonist of ERRg (14, 15) .
Despite a recent report demonstrating that phenolic acyl hydrazone is a selective agonist of ERRb and ERRg, further study will be required to prove that phenolic acyl hydrazone is a bona fide activator of ERRb and g (31). 4-OHT is widely used in the treatment of breast cancer and deactivates ERRg which was proposed as a favorable biomarker in human breast cancer (25) . As demonstrated in Figure 5 , both ERRg and DAX-1 are expressed in breast cancer cells and tissues. Furthermore, ERRg regulated the gene expression of DAX-1 in a positive manner, demonstrating that the DAX-1 promoter is a potential target of ERRg in vivo. Although the function of ERRg and DAX-1 in breast cancer is not completely understood, we speculate that there is both a positive and negative relationship between DAX-1 and ERRg, since DAX-1 acts as both a corepressor of ER and ERRg and as a regulator of the DAX-1 promoter. Recent reports indicated that ERRg regulates the ERRa promoter via a conserved hormone response element and epidermal growth factor signaling which affects ERRa transactivation in breast cancer cells (32, 33) . Since ERRa, ERRg and PGC-1a are co-expressed in breast cancer, their physiological function may be significantly correlated in breast cancer tissues.
It has been reported that DAX-1 interacts directly with various NRs and represses their transcriptional activity (4-6, 21,27) . Previous studies have demonstrated that DAX-1 uses its N-terminal repeating region, defined as the LXXLLcontaining interaction domain, for interaction with NRs (6) . In this study, we demonstrated that the LBD-like region of DAX-1 interacts with ERRg. We also found that DAX-1 interacts with ERRa and b (data not shown). The AF-2 domain of ERRg was crucial for the interaction with DAX-1 and acted as a binding surface for competition with the coactivator PGC-1a ( Figure 7) . Depending on the binding region of the nuclear receptor with the corepressor, the repressive mechanism of the corepressor can be quite different. When the DBD of the nuclear receptor is involved in interaction with the corepressor, the DNA-binding of the nuclear receptor is blocked by the corepressor (34) . Inversely, if the AF-2 domain of the nuclear receptor interacts with the corepressor, the competition between coactivators and the corepressor occurs on the AF-2 surface of the nuclear receptor (35) . In the case of ERRg, the AF-2 domain interacts with DAX-1 and acts as a binding surface for interaction with the coactivator PGC-1a (Figure 8) .
Previously, we reported that the SHP promoter is a target of ERR (16) . In the current study, we suggest that DAX-1 is a target of ERRg. As demonstrated in Figure 6 , DAX-1 repressed the transcriptional activity of ERRg on the DAX-1 and SHP promoters. In addition, SHP also inhibited ERRg on the DAX-1 and SHP promoters. It is very interesting that ERRg regulates corepressor proteins, such DAX-1 and SHP, which act as repression modulators. Although both SHP and DAX-1 are involved in the regulation of the corepressor-mediated transactivation of NRs, their physiological functions are quite different from each other. While DAX-1 plays a role in steroidogenic tissues, SHP functions mainly in the liver (1) . We demonstrated that there is a correlation between ERRg and DAX-1 in breast cancer cells ( Figure 5 ). In the case of SHP, we confirmed using adenovirus that ERRg activated SHP gene expression in the pancreas, but not in the liver (data not shown). This demonstrated that tissue-specific target gene expression is modulated by ERRg. DAX-1 is also differentially regulated by ERRg, depending on the target tissue. The modulation of DAX-1 and SHP by ERRg in vivo needs to be examined further, in order to identify the physiological roles of ERRg, SHP and DAX-1.
Collectively, as depicted in Figure 9 , we hypothesize that ERRg activates the DAX-1 promoter, which in turn inhibits ERRg through coactivator competition. In this study, we demonstrated that DAX-1 is a potential target of ERRg. Our study provides a new insight into understanding the basic mechanisms of DAX-1 and ERRg, and is expected to provide clues for the identification of the functions of ERRg. 
